Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 27;12(2):1588–1601. doi: 10.1002/cam4.4969

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

The effect of PEPCK inhibitor, 3‐MP, in ER⁺ breast cancer. (A) The cell count of MCF‐7 (left) and T47D (right) cells treated with various dose of 3‐MP for 4 days. (B) The cell cycle analysis of MCF‐7 (left) and T47D (right) treated with 3‐MP for 72 h. *p = 0.03. (C) The transition of cell cycle of MCF‐7 cells treated with 3‐MP for indicated dose and duration. *p = 0.03. (D) The expression of downstream signals of mTORC1 and cell cycle associated molecules in MCF‐7 (left) and T47D (right) cells treated with different doses of 3‐MP for 72 h.